CurrentCareSourcePolicy N/A

Gonadotropin-Releasing Hormone Agonists — Lupron Depot Utilization Management Medical Policy

Defines prior authorization, approved indications, dosing regimens, durations, and conditions not recommended for coverage of Lupron Depot for members covered by CareSource; affects prescribers requesting medical-benefit coverage.

Policy Summary

PayerCareSource

PolicyGonadotropin-Releasing Hormone Agonists — Lupron Depot Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeMinor review (no material changes)

Effective DateN/A

Next Review DateFeb 12, 2025

Key ActionObtain prior authorization and document indication, dosing, prescriber specialty, and duration to meet the policy's authorization criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

multipleIndications listed

12 monthsEndometriosis max duration

3 monthsFibroids approval duration

PA requiredAuthorization

3 situationsNot recommended examples

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization & Coverage Criteria

Indication-specific Authorization Criteria

Covered when the listed indication-specific criteria and dosing/duration requirements are met.

Covered Indications: Approval is recommended if the request meets ONE of the indication-specific branches below

Each indication includes dosing and duration limits and may require specialty prescriber or consultation.

Endometriosis: Patient has endometriosis AND has tried ONE of: a combined oral contraceptive, a levonorgestrel-releasing IUD, or depot medroxyprogesterone injection unless contraindicated OR the patient has prior use of a GnRH agonist or antagonist.

Approve ONE dosing: 3.75 mg IM once monthly OR 11.25 mg IM once every 3 months. Initial use: up to 6 months; retreatment only with add-back therapy; total duration limited to 12 months.

Uterine Leiomyomata (fibroids): Indication of uterine leiomyomata (fibroids) for preoperative hematologic improvement or as bridge therapy; prescribed intent documented.

Approve for 3 months. Approve ONE dosing: 3.75 mg IM once monthly OR 11.25 mg IM once every 3 months. Policy references ACOG guidance and recommends consideration of add-back therapy.

Prostate Cancer: Advanced or palliative prostate cancer AND prescribed by or in consultation with an oncologist.

Approve for 1 year. Approve ONE dosing: 7.5 mg IM once monthly OR 22.5 mg IM once every 3 months OR 30 mg IM once every 4 months OR 45 mg IM once every 6 months. Oncology reviews may be managed by eviCore.

Breast Cancer: Premenopausal breast cancer AND prescribed by or in consultation with an oncologist.

Approve for 1 year. Approve ONE dosing: 3.75 mg or 7.5 mg IM once monthly OR 11.25 mg or 22.5 mg IM once every 3 months.

Gender Dysphoria (pubertal suppression): Diagnosis of gender dysphoria requiring pubertal suppression AND prescribed by or in consultation with an endocrinologist or clinician specializing in transgender care.

Approve for 1 year. Approve ONE dosing: 3.75 mg or 7.5 mg IM once monthly OR 11.25 mg or 22.5 mg IM once every 3 months OR 30 mg IM once every 4 months OR 45 mg IM once every 6 months.

Other oncology and supportive uses: Oncology-related indications (e.g., head and neck salivary gland tumors with recurrent/unresectable/metastatic AND androgen receptor–positive disease, ovarian cancer, uterine cancer, preservation of ovarian function during chemotherapy, prophylaxis or treatment of uterine bleeding in hematologic malignancy) AND prescribed by or in consultation with an oncologist.

Approve typically for 1 year. Approve dosing per listed regimens (examples include 3.75 mg monthly; 11.25 or 22.5 mg q3 months; 30 mg q4 months; 45 mg q6 months). Some oncology indications are managed by eviCore and require oncologist documentation.

Abnormal Uterine Bleeding: Diagnosis of abnormal uterine bleeding requiring medical management.

Approve for 6 months. Approve ONE dosing: 3.75 mg IM once monthly OR 11.25 mg IM once every 3 months.

Premenstrual Disorders (PMS/PMDD): Patient is >= 18 years AND has severe, refractory premenstrual symptoms per prescriber AND has tried ONE of: a combined oral contraceptive OR an SSRI.

Approve for 1 year. Approve ONE dosing: 3.75 mg IM once monthly OR 11.25 mg IM once every 3 months.

Fertility/Ovarian Function Preservation: Use for preservation of ovarian function/fertility in patients undergoing chemotherapy AND prescribed by or in consultation with an oncologist.

Approve for 1 year. Approve ONE dosing: 3.75 mg IM once monthly OR 11.25 mg IM once every 3 months. Concurrent fertility preservation measures should be pursued per oncology guidance.

Uterine Cancer: Diagnosis of uterine cancer AND prescribed by or in consultation with an oncologist.

Approve for 1 year. Approve ONE dosing: 7.5 mg IM once monthly OR 22.5 mg IM once every 3 months OR 30 mg IM once every 4 months OR 45 mg IM once every 6 months.

Coverage of Lupron Depot is not recommended for certain conditions due to limited supportive evidence or unacceptable risk from hypoestrogenism. Explicitly listed conditions include menstrual migraine, where GnRH analogs can reduce migraine but carry significant adverse effects such as severe vasomotor symptoms and marked bone density loss, and polycystic ovarian syndrome (PCOS), for which review articles and international guidelines do not recommend GnRH agonists as a treatment modality. Requests for these indications are not supported by this policy.

Use of Lupron Depot for indications that are not specifically enumerated in the policy’s Recommended Authorization Criteria is not supported and is considered not recommended for approval; the criteria will be updated if new published data become available.

Dosing Strengths, Regimens & Codes

Dosing strengths and regimens (as listed)mixed

3.75 mg	Lupron Depot 3.75 mg IM once every month (dosing option listed)
7.5 mg	Lupron Depot 7.5 mg IM once every month (dosing option listed)
11.25 mg	Lupron Depot 11.25 mg IM once every 3 months (dosing option listed)
22.5 mg	Lupron Depot 22.5 mg IM once every 3 months (dosing option listed)
30 mg	Lupron Depot 30 mg IM once every 4 months (dosing option listed)
45 mg	Lupron Depot 45 mg IM once every 6 months (dosing option listed)

Prior Auth, Documentation & Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required for medical-benefit coverage of Lupron Depot. Approval is contingent on meeting the coverage criteria and dosing in this policy. Requests for doses outside the dosing regimens documented in this policy will be reviewed case-by-case by a clinician (e.g., Medical Director or Pharmacist). Approvals are provided for the durations noted in the policy (months = 30 days).

Prior authorization required for medical-benefit coverage
Requests for non-standard dosing considered case-by-case by clinical review
Approvals limited to durations specified in policy

Step Therapy

Step Therapy — Endometriosis

For endometriosis, step therapy is required: the patient must have tried ONE of the following first-line therapies unless contraindicated or the patient has prior use of a GnRH agonist/antagonist: A) combination oral contraceptives or a levonorgestrel-releasing intrauterine system (e.g., Mirena, Liletta); OR B) depo‑medroxyprogesterone injection; OR C) oral progestin (e.g., norethindrone). If step therapy is not met and no exception applies, authorization will be denied.

Key Definitions

Add‑back therapy — definition and role

DefinitionConcurrent low‑dose estrogen and/or progestin given with GnRH agonists to mitigate hypoestrogenic effects such as decreased bone mineral density and vasomotor symptoms.

PurposeReduce hypoestrogenic adverse effects (eg, bone density loss, vasomotor symptoms) associated with GnRH agonist therapy.

Common formulationsLow‑dose estrogen alone, low‑dose progestin alone, or combined estrogen‑progestin regimens; type and dose depend on patient preference and symptom severity.

When requiredRecommended for longer courses of GnRH agonist therapy (eg, retreatment or regimens >6 months) and considered in management of fibroids per ACOG guidance.

Clinical guidanceACOG and related society guidance note add‑back therapy may mitigate bone mineral density loss and should be individualized by type, dose, and route.

Clinical Background

Lupron Depot (leuprolide acetate) is a gonadotropin-releasing hormone (GnRH) agonist used in multiple gynecologic and oncologic contexts to suppress gonadal hormone production. Its clinical uses include management of endometriosis and uterine leiomyomata, and treatment or palliative management in certain cancers; however, prolonged hypoestrogenism from therapy can cause significant adverse effects (for example, vasomotor symptoms and loss of bone density), which informs duration limits and the consideration of add-back therapy for some indications.